Navigation Links
Shire Announces FDA Approval of VPRIV(TM) (velaglucerase alfa for injection) for the Treatment of Type 1 Gaucher Disease
Date:2/26/2010

.prop5='External Link';s.eVar3=s.prop5;s.prop15='85554402';s.tl(this,'o','ExternalLink');" target='_blank' href="http://www.onepath.com">http://www.onepath.com or call 1-(866)-888-0660. For more information about Gaucher disease, please visit http://www.GaucherPatients.com.

Indications and Usage

VPRIV(TM) (velaglucerase alfa for injection) is a hydrolytic lysosomal glucocerebroside-specific enzyme indicated for long-term enzyme replacement therapy for pediatric and adult patients with Type 1 Gaucher disease

    Dosing and Administration

    - 60 Units/kg administered every other week as a 60-minute intravenous
      infusion.

    - Patients currently being treated with imiglucerase for Type 1 Gaucher
      disease may be switched to VPRIV. Patients previously treated on a
      stable dose of imiglucerase are recommended to begin treatment with
      VPRIV at that same dose when they switch from imiglucerase to VPRIV.

    - Physicians can make dosage adjustments on an individual patient basis
      based on achievement and maintenance of therapeutic goals. Clinical
      trials have evaluated doses ranging from 15 Units/kg to 60 Units/kg
      every other week.


'/>"/>
SOURCE Shire Pharmaceutical
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Shire Appoints Sylvie Gregoire President of Human Genetic Therapies Business
2. Shires ELAPRASE(R) (idursulfase) Approved in Japan for the Treatment of Hunter Syndrome
3. Shire Divests Non-Core Product Portfolio to Almirall
4. Correction: Shire plc: Third Quarter 2007 results date notification November 1, 2007
5. David Mott Appointed Non Executive Director at Shire
6. Shire plc: Board Changes
7. Alba Therapeutics Corporation and Shire plc Enter Into $325 Million ex-US, ex-Japan Licensing Agreement to Develop and Commercialize AT-1001
8. Shire Expands its Gastrointestinal Portfolio Through In-Licensing Celiac Disease Phase 2 Product From Alba Therapeutics Corporation
9. FDA Approves Additional Dosage Strengths of Shires ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients
10. Texas Boy Receives Wheelchair From New Hampshire Couples Recently Deceased Granddaughter
11. Shire Engages Palio
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... , Dec. 22, 2014  Alternative Energy ... that it has signed a letter of intent ... has developed and patented a nanotechnology-based development platform ... products that enable rapid on-site collection and testing ... and health issues in an immediate, non-invasive and ...
(Date:12/22/2014)... 2014 The American Journal ... original research, reviews and editorials addressing developments and ... today published a provocative article exploring the role ... and potential treatment of prostate cancer. , ... proposes the possibility that there could be a ...
(Date:12/19/2014)... (PRWEB) December 19, 2014 Bioject ... developer and manufacturer of needle-free injection technology, today ... with Immunomic Therapeutics, Inc. (“ITI”) for ITI to ... with its LAMP™ vaccine platform. , In ... exclusive Worldwide license to the Biojector®-2000 that triggers ...
(Date:12/19/2014)... Dec. 19, 2014 Naurex Inc., a biopharmaceutical ... for diseases of the central nervous system, today announced ... executive officer, will present at the 33 rd ... take place at 3:00 p.m. PST on Tuesday, January ... San Francisco, Calif. ...
Breaking Biology Technology:ALNE Announces Intention To Acquire BioTechPharma 2Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 2Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 3Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 4Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 2Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 3Naurex to Present at 33rd Annual J.P. Morgan Healthcare Conference 2
... that do not specialize in software, but incorporate software-based ... more often than not, overlook the importance of protecting ... feature or the most prevalent feature of the product, ... and should be protected. , ,For example, many ...
... MADISON Health statistics are often broken down into categories ... meaningless concept that has no basis in biology or genetics. ... at a symposium titled Race, Genetics & Disease at Grainger ... Holtz Center for Science and Technology Studies sponsored the ...
... compete for $22,000 in awards this Friday as part ... Plan Competition . Fourteen teams of aspiring student entrepreneurs, ... their plans for technology-based businesses to a panel of ... UW System, this competition is the only activity on ...
Cached Biology Technology:Beyond the screws and gears: Protecting your products by protecting your software 2Symposium examines the effect of race on genetics and disease 2Students compete for $22,000 in Tech Business Plan Competition 2Students compete for $22,000 in Tech Business Plan Competition 3
(Date:12/10/2014)... DIEGO , Dec. 9, 2014 CIE ... collaboration catalyst that provides the connective tissue that enhances ... enabling them to easily share client-level information; earned a ... to expand to organizations serving seniors aging in community ... Diego" partner on December 11 th 4-6p. ...
(Date:12/10/2014)... 2014     ...   Jifflenow, a leading ... for business-to-business (B2B) events, today announced a partnership ... near-field communication (NFC), Bluetooth low energy (BLE), and ... , Jifflenow will integrate its meeting ...
(Date:12/5/2014)... Utah , Dec. 4, 2014  Tute Genomics, ... raised $2.3 million in Series A1 funding led by ... investors also participated in the investment round. ... the healthcare community adopts next-generation sequencing and seeks new ... said Reid Robison , MD MBA, and CEO ...
Breaking Biology News(10 mins):Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 3Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 4Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 3Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 3
... to investigate how lethal viruses attack differently sized populations of ... to new methods of pest control. The project, funded by ... meal moth ( Plodia interpunctella ) and a virus it ... not. Dr Steve Sait from the University of Leeds ...
... Something strange happened in 1973. Republican president Richard Nixon -- ... the land of quotas and restrictions" -- signed the Endangered ... about ecological issues -- and the rapid decline of charismatic ... to pass the law 92-0. Sounding more Thoreauvian than Thatcherite, ...
... boat owner recognises the dilemma: environmentally friendly or effective. ... a way of reconciling these two almost unattainable aims. ... biocides in the paint, it is possible to both ... the environmental impact. "It,s very easy to make ...
Cached Biology News:No safety in numbers for moths and butterflies 2Dispatches from the edge of doom 2Dispatches from the edge of doom 3Dispatches from the edge of doom 4More effective and less risky when you paint the hull of your boat 2
... Custom design, The Bioactive peptides are ... display a biological behaviour or activity which ... for pharmaceutical, diagnostic, chemical and agro-food applications. ... obtain modified peptides with superior properties for ...
... This CLS number is a ... easily match Cornings product number. ... please order under the old ... customer service for assistance. ...
... with forced convection Temperature range 5 C ... C / 212 F Patented APT.line preheating ... DS controller Timer 0 to 24 h ... a tenth of a degree Independent adjustable ...
... your microarray data using Asuragens bioinformatics ... need from consultation to extensive data ... date methods. Utilize our expertise in ... Service or from your own microarray ...
Biology Products: